JPWO2022153246A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022153246A5 JPWO2022153246A5 JP2023542844A JP2023542844A JPWO2022153246A5 JP WO2022153246 A5 JPWO2022153246 A5 JP WO2022153246A5 JP 2023542844 A JP2023542844 A JP 2023542844A JP 2023542844 A JP2023542844 A JP 2023542844A JP WO2022153246 A5 JPWO2022153246 A5 JP WO2022153246A5
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- formulation according
- tablet formulation
- present
- maximum concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2100470.0A GB202100470D0 (en) | 2021-01-14 | 2021-01-14 | Solid tablet dosage for of ridinilazole |
| GB2100470.0 | 2021-01-14 | ||
| PCT/IB2022/050311 WO2022153246A1 (en) | 2021-01-14 | 2022-01-14 | Solid tablet dosage form of ridinilazole |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024503689A JP2024503689A (ja) | 2024-01-26 |
| JP2024503689A5 JP2024503689A5 (https=) | 2026-04-02 |
| JPWO2022153246A5 true JPWO2022153246A5 (https=) | 2026-04-02 |
Family
ID=74679044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023542844A Pending JP2024503689A (ja) | 2021-01-14 | 2022-01-14 | リジニラゾールの固形錠剤剤形 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12318487B2 (https=) |
| EP (1) | EP4277604A1 (https=) |
| JP (1) | JP2024503689A (https=) |
| KR (1) | KR20230131253A (https=) |
| CN (1) | CN116801867A (https=) |
| AU (1) | AU2022207756B2 (https=) |
| CA (1) | CA3145677A1 (https=) |
| GB (1) | GB202100470D0 (https=) |
| IL (1) | IL304354A (https=) |
| MX (1) | MX2023008249A (https=) |
| WO (1) | WO2022153246A1 (https=) |
| ZA (1) | ZA202306739B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023213878A1 (en) * | 2022-05-04 | 2023-11-09 | Summit (Oxford) Limited | Solid tablet dosage form of ridinilazole |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996016042A1 (de) | 1994-11-17 | 1996-05-30 | F. Hoffmann-La Roche Ag | Antibakterielle dibenzimidazol-derivate |
| HUP0303494A3 (en) | 2000-12-15 | 2009-08-28 | Vertex Pharma | Parmaceutical compositions containing bacterial gyrase inhibitors and uses thereof |
| DE60309701T2 (de) | 2002-06-13 | 2007-09-06 | Vertex Pharmaceuticals Inc., Cambridge | 2-ureido-6-heteroaryl-3h-benzoimidazol-4-carbonsäurederivate und verwandte verbindungen als gyrase und/oder topoisomerase iv inhibitoren zur behandlung von bakteriellen infektionen |
| WO2004041209A2 (en) | 2002-11-01 | 2004-05-21 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| EP1742637A4 (en) | 2004-04-23 | 2011-06-08 | Paratek Pharm Innc | TRANSCRIPTION FACTOR MODULATION COMPOUNDS AND METHODS OF USE |
| US7825154B2 (en) | 2005-08-12 | 2010-11-02 | The United States Of America As Represented By The Secretary Of The Army | Small molecule inhibitors of botulinum neurotoxins |
| AU2006311729A1 (en) | 2005-11-07 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Benzimidazole derivatives as gyrase inhibitors |
| GB0612428D0 (en) | 2006-06-22 | 2006-08-02 | Prolysis Ltd | Antibacterial agents |
| CA2563690C (en) | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
| FR2918566B1 (fr) * | 2007-07-11 | 2009-10-09 | Pierre Fabre Medicament Sa | Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine. |
| GB0821913D0 (en) * | 2008-12-02 | 2009-01-07 | Price & Co | Antibacterial compounds |
| EP3315124B1 (en) * | 2009-11-13 | 2021-01-06 | Astrazeneca AB | Bilayer tablet formulations |
| ES2568455T3 (es) | 2010-06-01 | 2016-04-29 | Summit Therapeutics Plc | Compuestos para el tratamiento de enfermedad asociada a Clostridium difficile |
| WO2011151620A1 (en) | 2010-06-01 | 2011-12-08 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile associated disease |
| IL310920A (en) * | 2015-01-27 | 2024-04-01 | Janssen Pharmaceutica Nv | Dispersible compositions |
| KR20190140011A (ko) * | 2017-04-28 | 2019-12-18 | 아사나 바이오사이언시스 엘엘씨 | 아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형 |
| US11512068B2 (en) * | 2017-10-05 | 2022-11-29 | Sandoz Ag | Process for the preparation of crystalline ridinilazole using acid addition salts |
| KR20210033483A (ko) * | 2018-07-19 | 2021-03-26 | 다케다 야쿠힌 고교 가부시키가이샤 | Cdc7 억제제를 갖는 약제학적 조성물 |
| KR102737283B1 (ko) | 2019-07-17 | 2024-12-03 | 서밋 (옥스포드) 리미티드 | 리디닐라졸 및 이의 결정 형태의 제조방법 |
-
2021
- 2021-01-14 GB GBGB2100470.0A patent/GB202100470D0/en not_active Ceased
-
2022
- 2022-01-14 CN CN202280010065.7A patent/CN116801867A/zh active Pending
- 2022-01-14 KR KR1020237027498A patent/KR20230131253A/ko active Pending
- 2022-01-14 AU AU2022207756A patent/AU2022207756B2/en active Active
- 2022-01-14 US US17/576,242 patent/US12318487B2/en active Active
- 2022-01-14 EP EP22700441.3A patent/EP4277604A1/en active Pending
- 2022-01-14 MX MX2023008249A patent/MX2023008249A/es unknown
- 2022-01-14 WO PCT/IB2022/050311 patent/WO2022153246A1/en not_active Ceased
- 2022-01-14 JP JP2023542844A patent/JP2024503689A/ja active Pending
- 2022-01-14 CA CA3145677A patent/CA3145677A1/en active Pending
-
2023
- 2023-06-30 ZA ZA2023/06739A patent/ZA202306739B/en unknown
- 2023-07-10 IL IL304354A patent/IL304354A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5816091B2 (ja) | ナトリウムオキシベートの即時放出投薬形態 | |
| JP6043281B2 (ja) | ４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１−イル）−１ｈ−ベンズイミダゾール−２−イル］−１ｈ−キノリン−２−オンラクテート一水和物を含む医薬組成物 | |
| US8449910B2 (en) | Stable compositions of famotidine and ibuprofen | |
| JP5351490B2 (ja) | ニフェジピン含有有核錠剤およびその製法 | |
| JP2016006081A (ja) | 浸食マトリックス中に１またはそれ以上のフマル酸エステルを含む医薬製剤 | |
| JP4316013B2 (ja) | エプロサルタン二水和物ならびにその製法および処方 | |
| JPH09143073A (ja) | 持続性ニフエジピン製剤 | |
| US20070059365A1 (en) | Novel formulation of ropinirole | |
| US20120121702A1 (en) | Controlled Release Azithromycin Solid Dosage Forms | |
| CA2361843C (en) | Swallowable tablets with high content of n-acetylcysteine | |
| US10702520B1 (en) | Pharmaceutical compositions of posaconazole | |
| JP5208729B2 (ja) | 徐放性錠剤の製造方法 | |
| JP3751287B2 (ja) | 小型化されたニフェジピン有核錠剤 | |
| EP2701689B1 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
| WO2014006636A2 (en) | Stable compositions of fesoterodine | |
| WO2022225489A1 (en) | A bilayer tablet formulation comprising amorphous dapagliflozin and metformin | |
| JP2013542974A (ja) | 重炭酸塩を含んでなる医薬組成物、並びに尿路結石症及び関連疾患の治療及び／又は予防における医薬としてのこれらの使用 | |
| US20060002997A1 (en) | Nitrofurantoin controlled release dosage form | |
| JP2007529564A5 (https=) | ||
| TW202143959A (zh) | 一種非布司他片 | |
| KR101093781B1 (ko) | ｐＨ조절제를 함유하는 목시플록사신 고형 조성물 | |
| JP2021518422A (ja) | レナリドミドを含む医薬組成物 | |
| JPWO2022153246A5 (https=) | ||
| CN117815197A (zh) | 一种瑞巴派特缓释制剂及其制备方法和应用 | |
| CN101677960A (zh) | 美金刚胺的药物组合物 |